title: EMA policy on transparency is "strikingly" similar to deal struck with drug company, say experts.
authors.affiliation: The BMJ.
authors.forename: Peter
authors.initials: P
authors.lastname: Doshi
mesh_terms: D022126:Access to Information; D000068879:Adalimumab; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D017277:Drug Approval; D005062:European Union; D006077:Government Agencies; D006291:Health Policy; D007400:Interprofessional Relations
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab